Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq.

British journal of cancer - 1 Apr 2023

Markham John F, Fellowes Andrew P, Green Thomas, Leal Jose Luis, Legaie Roxane, Cullerne Darren, Morris Tessa, John Tom, Solomon Ben, Fox Stephen B

Abstract excerpt

BACKGROUND: Targeted RNA sequencing (RNA-seq) from FFPE specimens is used clinically in cancer for its ability to estimate gene expression and to detect fusions. Using a cohort of NSCLC patients, we sought to determine whether targeted RNA-seq could be used to measure tumour mutational burden (TMB) and the expression of immune-cell-restricted genes from FFPE specimens and whether these could predict response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to RNA-Seq

Share to Sequence Analysis, RNA

Source

Open in PubMed Open full text

Identifiers

PMID: 36572732
DOI: 10.1038/s41416-022-02105-w
PMCID: PMC10006283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq.PMID 36572732Read ↗

RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual BiosamplesSemantic proximity Read ↗

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity Read ↗

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerSemantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.Semantic proximity Read ↗

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.Semantic proximity Read ↗

Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.Semantic proximity Read ↗

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors.Semantic proximity Read ↗

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment OutcomesSemantic proximity Read ↗

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.Semantic proximity Read ↗

Estimating tumor mutational burden from RNA-sequencing without a matched-normal sampleSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.